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The findings of randomised controlled trials
confirm that St John’s wort (Hypericum
perforatum L) is effective in reducing symptoms
in mild to moderate depression, but few studies
have focused on the effect on anxiety symptoms.
Most studies have employed observer-rated
scales to measure treatment outcome, only few
used self-rated scales. We sought to examine
these issues in a cohort of members of the
depression self-help organisation Depression
Alliance UK (n=39). Hospital Anxiety and
Depression (HADS) scales were used at baseline,
prior to St John’s wort administration, and for
subsequent assessments at weeks 4, 8 and 12.
A subject-rated version of the Clinical Global
Impression – Improvement (CGI-I) scale was
employed at follow-up assessments. HADS
scores were significantly reduced after taking 
St John’s wort, particularly for those reporting
milder depression and more severe anxiety.
HADS scores compared well with patient
improvement ratings, indicating the feasibility 
of use in this population. Controlled studies 
are needed in a larger cohort to examine 
these findings, before definitive conclusions can
be made.
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Introduction
Investigations into the efficacy and tol-
erability of St John’s wort (Hypericum
perforatum L) in mild to moderate
depression have produced mixed
results. In one recent study1, 375
depressed patients (DSM-IV diagnosis;
HAMD 17-item score, 18–25) were ran-
domised to six weeks of St John’s wort
(extract WS5570) or placebo. St John’s
wort was associated with significantly
better response rates than placebo
(52.7% vs 42.3%) and significantly
greater reductions in HAMD scores (9.8
vs 7.1). Side effects and tolerability
were similar between the groups. 
The mean HAMD (17-item) score at
baseline in this study was 21.9. In an
earlier study2, where baseline HAMD
(21-item) scores averaged 19.45, there
were greater differences between 
St John’s wort and placebo. In that
study, 159 depressed patients (ICD-10
diagnosis; HAMD 21-item score, 16-24)
were randomised to St John’s wort
(ZE117) or placebo. Response rates
were significantly better for St John’s
wort (56%) than placebo (15%), and
reductions in HAMD scores were sig-
nificantly greater in the active group
(9.6 vs 0.8). Once more, side effects
and tolerability were similar between
the groups. The severity of depression
at baseline appears to be an indicator
for the efficacy of St John’s wort. 
10.1185/135525703125002342
Two studies that failed to find a 
difference between St John’s wort and
placebo set higher thresholds for
depression severity3,4, although it
should be noted that in the Davison
study3 sertraline did not differ from
placebo either. Both studies set an
inclusion criterion of 20 on HAMD (17-
item). However, the consensus in trails
involving St John’s wort indicate that it
is more efficacious in patients with
mild to moderate depression.5
Other studies have compared 
St John’s wort with traditional antide-
pressants. In one study6, 30 depressed
patients (DSM-IV diagnosis; HAMD
score ≥ 17, version not specified) were
randomised to St John’s wort (LI 160)
or sertraline for seven weeks. HAMD
scores were significantly reduced in
both groups, but did not differ from
each other (St John’s wort 8.4; sertra-
line 9.1), nor did they differ on
response rates (47% vs 40%). Both
groups reported similar side effects and
tolerability. In a larger study7, 240
depressed patients (ICD-10 diagnosis;
HAMD 21 score, 16–24) were ran-
domised to St John’s wort (ZE117;
n=126) or fluoxetine (n=114) for six
weeks. HAMD scores were slightly
more reduced for St John’s wort than
fluoxetine (but not significantly), but
overall response rates were significant-
ly better for St John’s wort (P = 0.005).
Side effects were less common with St
John’s wort (8%) than fluoxetine (23%). 
Comparative studies are not restrict-
ed to SSRIs; in one study 324 depressed
patients (ICD-10 diagnosis; HAMD 17
score ≥ 18) were randomised to St
John’s wort (ZE117; n=157) or
imipramine (n=167) for six weeks8.
HAMD reductions were similar
between the groups (St John’s wort,
10.4; imipramine, 9.4), although St
John’s wort was found to be superior
in respect of anxiety-somatisation
items. Side effects were less common
with St John’s wort (39%) than
imipramine (63%); side effects led to
withdrawal in 16% of those taking
imipramine, and 3% with St John’s
wort. Estimates of side effects with St
John’s wort range between 12% and
38% of cases9, with one meta-analysis
suggesting around 20%.5 Furthermore,
St John’s wort may interact adversely
with traditional antidepressants.10,11
We previously conducted a retrospec-
tive analysis of data from members of
the self-help organisation, Depression
Alliance (UK).12 One-half of the 452 
subjects reported using St John’s wort,
50% of whom reported improvement in
depressive symptoms within four
weeks. This was more pronounced for
those with mild (compared to more
severe) symptoms, and less noticeable
for those who took St John’s wort
alongside other antidepressants. Side
effects were reported by one-quarter of
the St John’s wort users. 
We present prospective data that
evaluate the effectiveness of St John’s
wort in a cohort of members of
Depression Alliance, over a course of
12 weeks. There has been little focus
on the effect of St John’s wort on 
anxiety symptoms, although one study
noted marked decreases in depressive
agitation and anxiety symptoms with St
John’s wort.13 The relative benefits in
respect of age and gender have also
received little attention. Another aim of
the study was to assess the feasibility of
using the HADS in this population,
with particular reference to the com-
pletion of scales, and the relation
between HADS scores and scores on a
subject-rated version of the CGI-I. 
Method
Subjects
Members of the UK depression 
self-help organisation ‘Depression
Alliance’ were contacted and supplied
with the baseline HADS, to determine
potential suitability for inclusion.
Respondents taking medications
known to interact with St John’s wort,
those with a history of self-harm or sui-
cide, and pregnant or breastfeeding
women were excluded. Thirty-nine
subjects were included; the mean age
was 43.69 (standard deviation, 13.07),
range 22-78 years; there were 19 men
and 20 women. Ethical approval was
granted by the Southampton & South
West Hants Local Research Ethics
Committee, in accordance with the
principles of the Declaration of
Helsinki (S39/00).
Materials and procedure
The subjects were sent supplies of 
St John’s wort by the St John’s wort
Information Centre, Brackley, (LI 160,
300mg daily) and further HADS 
questionnaires to be completed after 4,
8 and 12 weeks of the study. The sub-
ject-rated version of the CGI-I scale was
also completed at weeks 4, 8 and 12. 
Outcome measures in antidepressant
studies are frequently examined using
observer-rated scales. Patient-rated
scales are used less frequently, but can
provide valid and reliable data. 
The Hospital Anxiety and Depression
Scale (HADS; 14) was designed to elicit 
anxiety and depressive symptoms in
medical patients. The scale is brief and
simple to complete, employing 14 items
(7 for each of anxiety and depressive
symptoms). Furthermore, as the scale
does not include severe symptoms, it
may be better suited to milder forms of
psychiatric illness15 than more frequent-
ly used scales. In an extensive review
by Herrmann15, it was established that
HADS is well accepted by patients, with
reported acceptance of around 95%.
Drawing on a wide range of studies, the
HADS was shown to have good relia-
bility, with internal consistencies rang-
ing from 0.80 to 0.93 (Cronbach alphas)
and high retest reliability (r>0.80) for
up to two weeks. Herrman’s study also
points to high validity, in respect of
consistent factor analyses and high dis-
criminant and concurrent validity. 
The original authors14 recommended
two cut-off points in respect of total
HADS scores to determine levels of
anxiety and depression: 8 for possible
illness, 11 for probable illness.
Herrmann15 reports several studies that
reflect sensitivity and specificity of 0.8
or higher for these cut-off points to
reliably detect those conditions. The
author also reports that the HADS
remains robust in both cross-sectional
and longitudinal studies. In those 
studies, it was noted that women 
generally score higher than men on
HADS anxiety, with no significant 
differences for gender on the depression
subscale. HADS anxiety scores tended to
be higher in those aged 30–59, and
lower in those over 70 years. Meanwhile
HADS depression scores tended to be
highest in those aged 50–59, but lowest
in those under 30 years. 
The HADS has been used as an 
outcome measures in many randomised
controlled trials. In the Hampshire
Depression Project16 the effect of a com-
prehensive educational programme, 
targeted at primary care, was assessed
using the HADS to examine clinical 
outcome. The HADS was also used to
demonstrate the efficacy of escitalopram
in treating anxiety and depression17, and
16 Use of St John’s wort in members of depression self-help organisation
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for examining the efficacy of venlafax-
ine in treating Generalised Anxiety
Disorder (GAD;18). There are few stud-
ies that examine the use of the scale in
a depression self-help group, however
one study19 investigated this in 341
members of the ‘Fellowship of
Depressives Anonymous’, finding
robust psychometric properties and
good internal reliability in that popula-
tion. No studies have evaluated the use
of HADS during use of St John’s wort. 
A subject-rated version of the Clinical
Global Impressions – Improvement
scale (CGI-I)20 was used to examine ill-
ness improvement at weeks 4, 8 and 12. 
Results
Table 1 shows the HADS anxiety and
depression scores for the sample.
HADS anxiety scores were significantly
reduced at both the four-week (t=
3.768, df 38, P = 0.001) and eight-week
assessments (t= 2.266, df 38, P = 0.029).
The HADS depression scores were sig-
nificantly reduced at week 4 (t= 5.983,
df 38, P < 0.001). 
A stepwise regression was conducted
for HADS scores at each time point to
establish which of the variables con-
tributed most to the overall variance of
those scores. In respect of baseline
scores, HADS anxiety scores were 
predicted by gender and depression
severity (r 2 = 0.49; F = 17.179, df 2, 38 P
< 0.001); no single variable uniquely con-
tributed to HADS depression scores. At
week 4, HADS anxiety scores were pre-
dicted by baseline severity ratings of anx-
iety and depression (r 2 = 0.29; F = 8.564,
df 2, 38 P = 0.001), while only depression
severity ratings at baseline predicted
HADS depression scores at week 4 (r2 =
0.39; F = 23.796, df 1, 38 P < 0.001). At
week 8, HADS anxiety scores were pre-
dicted by baseline ratings of depression
severity (r2 = 0.23; F = 11.164, df 1, 38 P
= 0.002), while baseline severity ratings
of anxiety and depression, and age, pre-
dicted HADS depression scores at week
8 (r2 = 0.43; F = 10.617, df 3, 38 P <
0.001). At 12-week follow-up, HADS
anxiety scores were predicted by base-
line ratings of depression severity (r2 =
0.19; F = 8.830, df 1, 38 P = 0.005), while
baseline severity ratings of anxiety and
depression predicted HADS depression
scores at week 12 (r2 = 0.39; F = 13.153,
df 2, 38 P < 0.001).
Main effects for between-group analy-
ses were conducted using one-way
ANOVA. There was no effect for age
group for either of the HADS scores at
any time, but women reported signifi-
cantly higher HADS anxiety scores than
men at baseline (F = 28.857, df 1,38 P <
0.001) and week 4 (F = 7.488, df 1,38 P
= 0.009). There was a significant effect
for baseline severity of anxiety on HADS
anxiety scores at week 4 (F = 5.399, df 2,
38 P = 0.009), with those rated as proba-
bly anxious at baseline returning signifi-
cantly higher HADS anxiety scores at
week 4, than those rated as having no
clinical evidence of anxiety (normal) at
baseline (P =0.042). However, there was
a significant effect for baseline ratings of
depression severity on HADS anxiety
and depression scores at all follow-up
assessments, and for HADS anxiety
scores at baseline. Those rated as proba-
bly depressed reported significantly high-
er HADS depression scores, than those
rated as normal, throughout the study. 
The change in HADS scores between
time points, for each sub-category of
variable, was assessed using paired-
samples t-tests. In subjects aged under
40 years, HADS anxiety and depression
scores were significantly reduced at
week 4 (t = 2.400, df 11, P = 0.035; and
t = 3.895, df 11, P = 0.002 respectively)
and week 8 (t = 2.276, df 11, P = 0.044;
t = 2.345, df 11, P = 0.039). These were
also significantly reduced at week 4 
(t = 3.059, df 17, P = 0.007; t = 5.030, df
17, P < 0.001) and week 12 (t = 2.547,
df 17, P = 0.021; t = 3.757, df 17, P =
0.002) for those aged 50 years and over.
However, both HADS scores remained
relatively stable for those aged 40 to 49
years. For female subjects, HADS 
anxiety and depression scores were 
significantly reduced at week 4 (t =
3.591, df 19, P = 0.002; t = 3.814, df 19,
P = 0.001) and week 8 (t = 3.535, df 19,
P = 0.002; t = 2.833, df 19, P = 0.011),
while the only notable change for men
was a significant reduction in HADS
Table 2. HADS scores by CGI-Improvement rating 
HADS score: Baseline Week 4 % increase
(decrease)
(n) Anx Dep Anx Dep Anx Dep
CGI-I F1 1 0
2 9 11.22 7.89 7.22 4.00 (35.65)* (49.30)*
3 13 12.69 9.62 10.38 6.54 (18.20)* (32.02)*
4 14 13.29 11.86 12.29 9.64 (7.52) (18.72)*
5 3 9.33 11.67 10.33 7.67 10.72 (34.28)
6 0
7 0
Week 4 Week 8 % increase
(decrease)
Anx Dep Anx Dep Anx Dep
CGI-I F2 1 3 9.33 5.33 5.67 2.33 (39.23) (56.29)*
2 8 6.75 4.63 5.38 3.88 (20.30)* (16.20)
3 13 11.15 7.46 9.46 6.46 (15.16)* (13.40)
4 12 11.42 8.08 11.08 8.58 (2.98) 6.19
5 3 13.00 10.67 15.00 12.00 15.38 12.46
6 0
7 0
Week 8 Week 12 % increase
(decrease)
Anx Dep Anx Dep Anx Dep
CGI-I F3 1 7 6.14 2.29 3.57 1.29 (41.86) (43.67)*
2 8 7.88 5.50 6.75 3.88 (14.34) (29.45)
3 11 9.82 7.27 10.73 7.00 9.27 (3.71)
4 9 10.00 8.67 9.22 8.11 (7.80) (6.46)
5 4 14.25 10.75 15.25 12.00 7.02 11.63
6 0
7 0
CGI-I scores: 1, Very much improved; 2, Much improved; 3, Slightly improved; 
4, No change in symptoms; 5, Slightly worse; 6: Much worse; 7, Very much worse.
* Significant difference between time points.
depression scores at week 4 (t = 4.757,
df 18, P < 0.001). 
Severity ratings of anxiety and
depression demonstrated quite differ-
ent profiles to one another. For those
rated as probably anxious (severe) at
baseline, HADS anxiety and depression
scores were significantly reduced at
week 4 (t = 4.564, df 26, P < 0.001; t =
5.432, df 26, P < 0.001) and week 8 (t
= 4.786, df 26, P < 0.001; t = 2.855, df
26, P = 0.008). All other ratings of anx-
iety severity showed no differences
between time points. For subjects rated
as normal and as ‘probably depressed’
(severe) on depression severity, HADS
depression scores remained relatively
stable, except for a significant decrease
in depression scores at week 4 
(normal: t = 2.374, df 7, P = 0.049;
probable t = 4.404, df 15, P = 0.001).
For those rated as possibly depressed
(mild to moderate), decreases in HADS
score were more widespread, with sig-
nificant decreases in HADS anxiety and
depression scores at week 4 (t = 2.622,
df 14, P = 0.020; t = 2.412, df 14, P =
0.004) and in anxiety scores at week 8 
(t = 2.272, df 14, P = 0.039). 
Changes in HADS scores were com-
pared to scores on the subject-rated ver-
sion of the CGI-I ratings (Table 2). 
At week 4 no subjects were ‘very much
improved’, but HADS anxiety and
depression scores were significantly
reduced for those who were ‘much
improved’ (t = 4.000, df 8, P = 0.004; 
t = 3.865, df 8, P = 0.005) and ‘slightly
improved’ (t = 4.629, df 12, P = 0.001; 
t = 3.682, df 12, P = 0.003). Depression
scores were also significantly reduced
for those who reported ‘no change in
symptoms’ (t = 2.987, df 13, P = 0.012).
At week 8, those who were ‘very much
improved’ showed decreases in HADS
anxiety and depression scores, which
was significant for the depression scores
(t = 5.196, df 2, P = 0.035). There was a
significant reduction in HADS anxiety
scores for those ‘much improved’ (t =
2.434, df 7, P = 0.045) and ‘slightly
improved’ (t = 2.587, df 7, P = 0.024).
For those subjects who showed no
improvement, or who were ‘slightly
worse’, HADS anxiety and depression
scores generally increased (although not
significantly). At week 12, both HADS
scores were much improved for those
‘very much improved’, fairly reduced for
those ‘much improved’, somewhat
reduced for those ‘slightly improved’ or
who showed ‘no improvement’, while
HADS anxiety and depression scores
increased for those subjects rated as
being ‘slightly worse’ on CGI-I; although
none of these changes were significant. 
Discussion
Following the administration of St John’s
wort, self-rated anxiety was significantly
reduced at weeks 4 and 8, and depres-
sion at week 4. HADS anxiety and
depression scores were significantly
reduced at weeks 4 and 8 for those aged
under 40, and at weeks 4 and 12 for
those aged 50 or over; there was no
effect for those aged 40 to 49. HADS
anxiety and depression scores were sig-
nificantly reduced for women at weeks 4
and 8, and women reported significant-
ly higher HADS scores than men at base-
line and week 4. There were no consis-
tent effects for men. HADS anxiety and
depression scores were significantly
reduced at weeks 4 and 8 for those
reporting the most severe anxiety at
baseline, while no effect was found for
those with mild, or no, anxiety at base-
line. HADS sub-scale scores were signif-
icantly reduced at week 4, and HADS
anxiety at week 8, for those reporting
milder depression at baseline, while no
consistent effect was found in this
respect for those with more severe, or
no, depression at baseline. Furthermore,
while there was a significant difference
in HADS anxiety scores, between those
reporting most anxiety and those report-
ing no anxiety at week 4, this effect was
no longer apparent at weeks 8 and 12.
However, a significant difference in both
HADS scores, between those reporting
most depression and those reporting
none, remained throughout the study.
Changes in HADS scores were generally
reflected by change in scores on the
global ratings. 
These results suggest that St John’s
wort can be successful in reducing self-
reported symptoms of depression and
anxiety, particularly for those reporting
more severe symptoms of anxiety and
milder symptoms of depression. This
supports previous evidence that St
John’s wort is more effective in mild to
moderate depression5, rather than more
severe forms. 3,4 The stepwise regression
analysis indicated that depression sever-
ity at baseline was a constant 
predictor of HADS score at follow-up
visits, supporting evidence that the 
efficacy of St John’s wort can depend on
baseline depression severity1-4. The sug-
gestion that St John’s wort might provide
greater benefit for those most anxious
has received little attention before,
although one study reported that St
John’s wort reduced depressive agitation
and anxiety13. Women scored more high-
ly on HADS anxiety scores than men at
baseline and week 4, which supports
data from previous findings15. Those
scores were significantly reduced at
weeks 4 and 8, lending support to the
finding that St John’s wort benefits those
with more severe anxiety. 
Caution is warranted when interpret-
ing findings from a small sample. There
were a number of findings of sufficient
magnitude to merit examination in a
larger cohort. It is possible that differ-
ent extracts of St John’s wort result in
different outcomes, and the precise
extracts needs to be specified.
Concurrent medication taken by the
participants was not recorded; not only
is there evidence of adverse interac-
tions between St John’s wort and tradi-
tional antidepressants10,11, and poorer
outcomes12, there is no certainty that
outcomes here were not the result of a
medication other than St John’s wort.
Furthermore, reported adverse events
were not recorded and these need to
be documented adequately.
Nevertheless, this pilot study pro-
duced some useful findings that could
be investigated more comprehensively
in a larger study. The findings here
confirmed the body of evidence that 
St John’s wort is efficacious to individu-
als reporting mild to moderate depres-
sion. It adds a tentative finding that this
may also be possible in individuals with
more severe anxiety. The HADS scale
was successfully used in this depression
self-help group population. 
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